CELLDEX THERAPEUTICS, INC. 8,520,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • March 1st, 2024 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 8,520,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 8,520,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,278,000 Shares pursuant to such option collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Leerink Partners LLC and Cowen and Company, LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used herein shall mean Le
